Bridging chemistry, engineering, biology & medicine to advance human health, transform research, and train the next generation of scientific leaders @Stanford
#ICYMI This year is the 10th anniversary of the Chemistry/Biology Interface (CBI) Training Program, which has brought together over 155 scientists-in-training from across chemistry, biology, engineering, and medicine PhD programs at Stanford.
Learn more: brnw.ch/21x6D0S
Our final version of human AGO2 led editing of RNA is out today in @NatureBiotech! Led by @noScandineHere, we got excited by the reduced immunogenic risk and efficacy advantages of using a human-derived protein for non-downregulatory RNA manipulation.
nature.com/articles/s41587-0…
Our final version of human AGO2 led editing of RNA is out today in @NatureBiotech! Led by @noScandineHere, we got excited by the reduced immunogenic risk and efficacy advantages of using a human-derived protein for non-downregulatory RNA manipulation.
nature.com/articles/s41587-0…
Thank you to Dr. Paul Mischel of @Stanford for yesterday’s IICD Seminar! 🧬
Dr. Mischel discussed how ecDNA drives cancer evolution, enabling tumor cells to rapidly adapt to changing environments and treatments.
Watch the recording here: piped.video/ofXvrnCPnd0?si=wGuF…
Our 13th Annual Stanford Neurosciences Symposium has begun! Our topic: Building the Brain. We’re exploring how our brains wire themselves up from a few cells into the three pounds of matter in our skulls that makes us who we are.
ALT Congratulations to our Institute Scholar Rebecca Pinals on winning the 2026 Dr. Laure Aurelian Biomedical Research Award, given to early-career faculty members conducting innovative basic or translational biomedical research.
A team including Gerald Crabtree, Institute Scholar Nathanael Gray, Stephen Hinshaw, Michael Green, CBI fellow Meredith Nix & co-lead author Sai Gourisankar, & Nucleus Director Daniel Fernandez built a molecule that flips BCL6 into a cancer kill switch: brnw.ch/21x6rur
ALT Diffuse large B-cell lymphoma. Tumors in mice disappeared after a few days of treatment with a Stanford Medicine-designed molecule that “glues” two proteins together and activates genes driving cell death. | Getty Images
That’s a wrap on #CRB60! Thank you to all the researchers who showed, from glycoRNA to bioluminescence to tuberculosis, just how far Carolyn Bertozzi’s legacy has traveled!
Today we're live from #CRB60, a symposium honoring our director Carolyn Bertozzi's legacy and impact on chemical biology. Speakers include Bertozzi lab alumni now leading their own research.
Session 4: Inventing Tomorrow's Medicines. Chair Stavroula Hatzios, with @StevenMBanik, Nicholas Agard, Lisa Marcaurelle, Matthew Hangauer, Peng Wu, and Penelope Drake; Hatzios closes. #CRB60
Now kicking off CRB60 is co-organizer @basktastic highlighting what I also agree is one of Carolyn’s most important contribution to science- her impact as a mentor and advisor @Stanford_ChEMH@Stanford